A Practitioner’s Guide to Prescribing Lamotrigine for Adults with Intellectual Disabilities

  • Jose de Leon


We developed this lamotrigine guideline using drug prescribing ­information and reviewing the available literature on relevant neuropsychiatric disorders in populations without intellectual disabilities because of the dearth of available literature on the population with intellectual disabilities. This guideline includes indications; contraindications; assessments prior to and during treatment; dosing with particular focus on dosing modifications required by drug–drug interactions, or personal characteristics; and adverse drug reactions. The procedures contained in this guideline may not fully account for all of the possible risks of treatment in this population because of the limited studies available; thus, there will be a need to periodically update this guideline as new information becomes available. Nevertheless, we believe that this guideline provides a useful resource for clinicians who treat epilepsy or mood disorders in adult individuals with intellectual ­disabilities. A lamotrigine drug utilization review that summarizes this guideline is described.


Intellectual Disability First Degree Atrioventricular Block Lamotrigine Dose Gastaut Syndrome Lamotrigine Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Aiken, C. B., & Orr, C. (2010). Rechallenge with lamotrigine after a rash: a prospective case series and review of the literature. Psychiatry (Edgmont), 7, 27–32.Google Scholar
  2. American Psychiatric Association. (2002). Practice guideline for the treatment of patients with bipolar disorder (revision). The American Journal of Psychiatry, 159(4 Suppl), 1–50.Google Scholar
  3. Anderson, G. D., Gidal, B. E., Messenheimer, J. A., & Gilliam, F. G. (2002). Time course of lamotrigine de-induction: impact of step-wise withdrawal of carbamazepine or phenytoin. Epilepsy Research, 49, 211–217.PubMedCrossRefGoogle Scholar
  4. Arana, A., Wentworth, C. E., Ayuso-Mateos, J. L., & Arellano, F. M. (2010). Suicide-related events in patients treated with antiepileptic drugs. The New England Journal of Medicine, 363, 542–551.PubMedCrossRefGoogle Scholar
  5. Argikar, U. A., & Remmel, R. P. (2009). Variation in glucuronidation of lamotrigine in human liver microsomes. Xenobiotica, 39, 355–363.PubMedCrossRefGoogle Scholar
  6. Arif, H., Buchsbaum, R., Pierro, J., Whalen, M., Sims, J., Resor, S. R., Jr., et al. (2010). Comparative effectiveness of 10 antiepileptic drugs in older adults with epilepsy. Archives of Neurology, 67, 408–415.PubMedCrossRefGoogle Scholar
  7. Arif, H., Buchsbaum, R., Weintraub, D., Koyfman, S., Salas-Humara, C., Bazil, C. W., Resor, S. R., Jr., & Hirsch, L. J. (2007). Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology, 68, 1701–1709.PubMedCrossRefGoogle Scholar
  8. Arif, H., Buchsbaum, R., Weintraub, D., Pierro, J., Resor, S. R., Jr., & Hirsch, L. J. (2009). Patient-reported cognitive side effects of antiepileptic drugs: predictors and comparison of all commonly used antiepileptic drugs. Epilepsy & Behavior, 14, 202–209.CrossRefGoogle Scholar
  9. Bastuji-Garin, S., Rzany, B., & Stern, R. S. (1993). Clinical classification of cases of toxic epidermal necrolysis: Stevens-Johnson syndrome and erythema multiforme. The Archives of Dermatology, 129, 92–96.PubMedCrossRefGoogle Scholar
  10. Bell, G. S., Mula, M., & Sander, J. W. (2009). Suicidality in people taking antiepileptic drugs: what is the evidence? CNS Drugs, 23, 281–292.PubMedCrossRefGoogle Scholar
  11. Ben-Menachem, E. (2007). Weight issues for people with epilepsy—a review. Epilepsia, 48(Suppl 9), 42–45.PubMedCrossRefGoogle Scholar
  12. Beran, R. G., & Gibson, R. J. (1998). Aggressive behaviour in intellectually challenged patients with epilepsy treated with lamotrigine. Epilepsia, 39, 280–282.PubMedCrossRefGoogle Scholar
  13. Besag, F. M., Berry, D. J., Pool, F., Newbery, J. E., & Subel, B. (1998). Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia, 39, 183–187.PubMedCrossRefGoogle Scholar
  14. Bhaumik, S., Branford, D., Duggirala, C., & Ismail, I. A. (1997). A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. Seizure, 6, 127–133.PubMedCrossRefGoogle Scholar
  15. Biton, V. (2006). Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy. Expert Opinion on Drug Metabolism & Toxicology, 2, 1009–1018.CrossRefGoogle Scholar
  16. Blum, D., Meador, K., Biton, V., Fakhoury, T., Shneker, B., Chung, S., et al. (2006). Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. Neurology, 67, 400–406.PubMedCrossRefGoogle Scholar
  17. Botts, S., Diaz, F. J., Santoro, V., Spina, E., Muscatello, M. R., Cogollo, M., et al. (2008). Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 32, 1453–1458.CrossRefGoogle Scholar
  18. Bowden, C. L., Asnis, G. M., Ginsberg, L. D., Bentley, B., Leadbetter, R., & White, R. (2004). Safety and tolerability of lamotrigine for bipolar disorder. Drug Safety, 27, 173–184.PubMedCrossRefGoogle Scholar
  19. Bowden, C. L., Calabrese, J. R., Ketter, T. A., Sachs, G. S., White, R. L., & Thompson, T. R. (2006). Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder. The American Journal of Psychiatry, 163, 1199–1201.PubMedCrossRefGoogle Scholar
  20. Brandt, C., Fueratsch, N., Boehme, V., Kramme, C., Pieridou, M., Villagran, A., et al. (2007). Development of psychosis in patients with epilepsy treated with lamotrigine: report of six cases and review of the literature. Epilepsy & Behavior, 11, 133–139.CrossRefGoogle Scholar
  21. Brodie, M. J. (2010). Antiepileptic drug therapy the story so far. Seizure, 19, 650–655.PubMedCrossRefGoogle Scholar
  22. Brodie, M. J., Wilson, E. A., Wesche, D. L., Alvey, C. W., Randinitis, E. J., Posvar, E. L., et al. (2005). Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia, 46, 1407–1413.PubMedCrossRefGoogle Scholar
  23. Buchanan, N. (1995). The efficacy of lamotrigine on seizure control in 34 children, adolescents and young adults with intellectual and physical disability. Seizure, 4, 233–236.PubMedCrossRefGoogle Scholar
  24. Burchell, B., Soars, M., Monaghan, G., Cassidy, A., Smith, D., & Ethell, B. (2000). Drug-mediated toxicity caused by genetic deficiency of UDP-glucuronosyltransferases. Toxicology Letters, 112–113, 333–340.PubMedCrossRefGoogle Scholar
  25. Calabrese, J. R., Sullivan, J. R., Bowden, C. L., Suppes, T., Goldberg, J. F., Sachs, G. S., et al. (2002). Rash in multicenter trials of lamotrigine in mood disorders: clinical relevance and management. The Journal of Clinical Psychiatry, 63, 1012–1019.PubMedCrossRefGoogle Scholar
  26. Carpay, J. A., Aalbers, K., Graveland, G. A., & Engelsman, M. (2009). Retention of new AEDs in institutionalized intellectually disabled patients with epilepsy. Seizure, 18, 119–123.PubMedCrossRefGoogle Scholar
  27. Chen, C., Veronese, L., & Yin, Y. (2000). The effects of lamotrigine on the pharmacokinetics of lithium. British Journal of Clinical Pharmacology, 50, 193–195.PubMedCrossRefGoogle Scholar
  28. Chen, H., Yang, K., Choi, S., Fischer, J. H., & Jeong, H. (2009). Up-regulation of UDP-glucuronosyltransferase (UGT) 1A4 by 17beta-estradiol: a potential mechanism of increased lamotrigine elimination in pregnancy. Drug Metabolism and Disposition, 37, 1841–1847.PubMedCrossRefGoogle Scholar
  29. Christensen, J., Petrenaite, V., Atterman, J., Sidenius, P., Ohman, I., Tomson, T., et al. (2007). Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. Epilepsia, 48, 484–489.PubMedCrossRefGoogle Scholar
  30. Colucci, R., Glue, P., Holt, B., Banfield, C., Reidenberg, P., Meehan, J. W., et al. (1996). Effect of felbamate on the pharmacokinetics of lamotrigine. The Journal of Clinical Pharmacology, 36, 634–638.PubMedGoogle Scholar
  31. Coskun, M., Bozkurt, H., & Zoroglu, S. (2009). Possible lamotrigine-induced mania in a child with autism spectrum disorder and epilepsy (letter). Journal of Clinical Psychopharma­cology, 29, 508–509.PubMedCrossRefGoogle Scholar
  32. Crawford, P., Brown, S., Kerr, M., & Parke Davis Clinical Trials Group. (2001). A randomized open-label study of gabapentin and lamotrigine in adults with learning disability and resistant epilepsy. Seizure, 10, 107–115.PubMedGoogle Scholar
  33. Davanzo, P. A., & King, B. H. (1996). Open trial lamotrigine in the treatment of self-injurious behavior in an adolescent with profound mental retardation. Journal of Child and Adolescent Psychopharmacology, 6, 273–279.PubMedCrossRefGoogle Scholar
  34. de Leon, J. (2003). Glucuronidation enzymes, genes and psychiatry. The International Journal of Neuropsychopharmacology, 6, 57–72.PubMedCrossRefGoogle Scholar
  35. de Leon, J., Armstrong, S. C., & Cozza, K. L. (2005). The dosing of atypical antipsychotics. Psychosomatics, 46, 262–273.PubMedCrossRefGoogle Scholar
  36. Depot, M., Powell, J. R., Messenheimer, J. A., Jr., Cloutier, G., & Dalton, M. J. (1990). Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine. Clinical Pharmacology and Therapeutics, 48, 346–355.PubMedCrossRefGoogle Scholar
  37. Dixon, R., Job, S., Oliver, R., Tompson, D., Wright, J. G., Maltby, K., et al. (2008). Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects. British Journal of Clinical Pharmacology, 66, 396–404.PubMedCrossRefGoogle Scholar
  38. Dolk, H., Jentink, J., Loane, M., Morris, J., de Jong-van den Berg, L. T., & EUROCAT Antiepileptic Drug Working Group. (2008). Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations? Neurology, 71, 714–722.PubMedCrossRefGoogle Scholar
  39. Doose, D. R., Brodie, M. J., Wilson, E. A., Chadwick, D., Oxbury, J., Berry, D. J., et al. (2003). Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients. Epilepsia, 44, 917–922.PubMedCrossRefGoogle Scholar
  40. Ebert, U., Thong, N. Q., Oertel, R., & Kirch, W. (2000). Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. European Journal of Clinical Pharmacology, 56, 299–304.PubMedCrossRefGoogle Scholar
  41. Ettinger, A. B., Kustra, R. P., & Hammer, A. E. (2007). Effect of lamotrigine on depressive symptoms in adult patients with epilepsy. Epilepsy & Behavior, 10, 148–154.CrossRefGoogle Scholar
  42. Ettinger, A. B., Weisbrot, D. M., Saracco, J., Dhoon, A., Kanner, A., & Devinsky, O. (1998). Positive and negative psychotropic effects of lamotrigine in patients with epilepsy and mental retardation. Epilepsia, 39, 874–877.PubMedCrossRefGoogle Scholar
  43. Fakhoury, T. A., Barry, J. J., Mitchell Miller, J., Hammer, A. E., & Vuong, A. (2007). Lamotrigine in patients with epilepsy and comorbid depressive symptoms. Epilepsy & Behavior, 10, 155–162.CrossRefGoogle Scholar
  44. Fountoulakis, K. N., & Vieta, E. (2008). Treatment of bipolar disorder: a systematic review of available data and clinical perspectives. The International Journal of Neuropsychopharmacology, 11, 999–1029.PubMedGoogle Scholar
  45. Franco, V., Mazzucchelli, I., Gatti, G., Specchio, L. M., La Neve, A., Papantonio, A., et al. (2008). Changes in lamotrigine pharmacokinetics during pregnancy and the puerperium. Therapeutic Drug Monitoring, 30, 544–547.PubMedGoogle Scholar
  46. French, J. A., & Faught, E. (2009). Rational polytherapy. Epilepsia, 50(Suppl 8), 63–68.PubMedCrossRefGoogle Scholar
  47. Gaffield, M. E., Culwell, K. R., & Lee, C. R. (2011). The use of hormonal contraception among women taking anticonvulsant therapy. Contraception, 83, 16–29.PubMedCrossRefGoogle Scholar
  48. Gamble, C., Williamson, P. R., Chadwick, D. W., & Marson, A. G. (2006). A meta-analysis of individual patient responses to lamotrigine or carbamazepine monotherapy. Neurology, 66, 1310–1317.PubMedCrossRefGoogle Scholar
  49. Gamble, C., Williamson, P. R., & Marson, A. G. (2006). Lamotrigine versus carbamazepine monotherapy for epilepsy. The Cochrane Database of Systematic Reviews, 25, CD001031.Google Scholar
  50. Geddes, J. R., Calabrese, J. R., & Goodwin, G. M. (2009). Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. The British Journal of Psychiatry, 194, 4–9.PubMedCrossRefGoogle Scholar
  51. Ghaemi, S. N. (2009). The failure to know what isn’t known: negative publication bias with lamotrigine and a glimpse inside peer review. Evidence-Based Mental Health, 12, 65–68.PubMedCrossRefGoogle Scholar
  52. Ghaemi, S. N., Shirzadi, A. A., Filkowski, M. (2008). Publication bias and the pharmaceutical industry: the case of lamotrigine in bipolar disorder. Medscape Journal of Medicine, 10, 211 Accessed 12 Apr 2011.
  53. Gidal, B. E., Walker, J. K., Lott, R. S., Shaw, R., Speth, J., Marty, K. J., et al. (2000). Efficacy of lamotrigine in institutionalized, developmentally disabled patients with epilepsy: A retrospective evaluation. Seizure, 9, 131–136.PubMedCrossRefGoogle Scholar
  54. GlaxoSmithKline. (2010). Lamictal (lamotrigine) tablets. Lamictal (lamotrigine) chewable dispersible tablets. Lamictal ODT (lamotrigine) orally disintegrating tablets (highlights of prescribing information). Research Triangle Park, NC: GlaxoSmithKline.Google Scholar
  55. GlaxoSmithKline. (2011). Lamictal XR (lamotrigine) extended-release tablets (highlights of prescribing information). Research Triangle Park, NC: GlaxoSmithKline.Google Scholar
  56. Grasela, T. H., Fiedler-Kelly, J., Cox, E., Womble, G. P., Risner, M. E., & Chen, C. (1999). Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy. Journal of Clinical Pharmacology, 39, 373–384.PubMedCrossRefGoogle Scholar
  57. Gualtieri, C. T., & Johnson, L. G. (2006). Comparative neurocognitive effects of 5 psychotropic anticonvulsants and lithium. Medscape General Medicine, 8, 46.PubMedGoogle Scholar
  58. Hachad, H., Ragueneau-Majlessi, I., & Levy, R. H. (2002). New antiepileptic drugs: review on drug interactions. Therapeutic Drug Monitoring, 24, 91–103.PubMedCrossRefGoogle Scholar
  59. Harden, C. L. (2008). Antiepileptic drug teratogenesis: what are the risks for congenital malformations and adverse cognitive outcomes? International Review of Neurobiology, 83, 205–213.PubMedCrossRefGoogle Scholar
  60. Harden, C. L., Pennell, P. B., Koppel, B. S., Hovinga, C. A., Gidal, B., Meador, K. J., et al. (2009). Practice parameter update: management issues for women with epilepsy – focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding. Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology, 73, 126–132.PubMedCrossRefGoogle Scholar
  61. Harris, E. C., & Barraclough, B. (1997). Suicide as an outcome for mental disorders. A meta-analysis. The British Journal of Psychiatry, 170, 205–228.CrossRefGoogle Scholar
  62. Herman, S. T. (2009). Adopting an orphan drug: Rufinamide for Lennox-Gastaut syndrome. Epilepsy Currents, 9, 72–74.PubMedCrossRefGoogle Scholar
  63. Hesdorffer, D. C., Berg, A. T., & Kanner, A. M. (2010). An update on antiepileptic drugs and suicide: are there definitive answers yet? Epilepsy Currents, 10, 137–145.PubMedCrossRefGoogle Scholar
  64. Hirsch, L. J., Weintraub, D. B., Buchsbaum, R., Spencer, H. T., Straka, T., Hager, M., et al. (2006). Predictors of lamotrigine-associated rash. Epilepsia, 47, 318–322.PubMedCrossRefGoogle Scholar
  65. Huber, B., May, T., & Seidel, M. (1998). Lamotrigine in multihandicapped therapy-resistant epileptic patients. Clinical Drug Investigation, 16, 263–277.PubMedCrossRefGoogle Scholar
  66. Jann, M. W., Hon, Y. Y., Shamsi, S. A., Zheng, J., Awad, E. A., & Spratlin, V. (2006). Lack of pharmacokinetic interaction between lamotrigine and olanzapine in healthy volunteers. Pharmacotherapy, 26, 627–633.PubMedCrossRefGoogle Scholar
  67. Jefferson, J. W. (2005). Lamotrigine in psychiatry: pharmacology and therapeutics. CNS Spectrums, 10, 224–232.PubMedGoogle Scholar
  68. Johannessen, S. I., & Tomson, T. (2006). Pharmacokinetic variability of newer antiepileptic drugs. When is monitoring needed? Clinical Pharmacokinetics, 45, 1061–1075.PubMedCrossRefGoogle Scholar
  69. Kalanin, V. V. (2007). Suicidality and antiepileptic drugs. Is there a link? Drug Safety, 30, 123–142.CrossRefGoogle Scholar
  70. Kanner, A. M., & Frey, M. (2000). Adding valproate to lamotrigine: a study of their pharmacokinetic interaction. Neurology, 55, 588–591.PubMedGoogle Scholar
  71. Kauffman, K. R., & Gerner, R. (1998). Lamotrigine toxicity secondary to sertraline. Seizure, 7, 163–165.Google Scholar
  72. Kennedy, G. M., & Lhatoo, S. D. (2008). CNS adverse events associated with antiepileptic drugs. CNS Drugs, 22, 739–760.PubMedCrossRefGoogle Scholar
  73. Kuehn, B. M. (2008). FDA warns of adverse events linked to smoking cessation drug and antiepileptics. The Journal of the American Medical Association, 299, 1121–1122.CrossRefGoogle Scholar
  74. Labiner, D. M., Ettinger, A. B., Fakhoury, T. A., Chung, S. S., Shneker, B., Tatum Iv, W. O., et al. (2009). Effects of lamotrigine compared with levetiracetam on anger, hostility, and total mood in patients with partial epilepsy. Epilepsia, 50, 434–442.PubMedCrossRefGoogle Scholar
  75. Lacy, C. F., Armstrong, L. L., Goldman, M. P., & Lance, L. L. (2009). Drug information handbook (18th ed.). Hudson, OH: Lexi-Comp.Google Scholar
  76. Large, C. H., Di Daniel, E., Li, X., & George, M. S. (2009). Neural network dysfunction in bipolar depression: clues from the efficacy of lamotrigine. Biochemical Society Transactions, 37(Pt 5), 1080–1084.PubMedCrossRefGoogle Scholar
  77. Levy, R. H., Ragueneau-Majlessi, I., Brodie, M. J., Smith, D. F., Shah, J., & Pan, W. J. (2005). Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy. Therapeutic Drug Monitoring, 27, 193–198.PubMedCrossRefGoogle Scholar
  78. Licht, R. W., Nielsen, J. N., Gram, L. F., Vestergaard, P., & Bendz, H. (2010). Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disorders, 12, 483–493.PubMedCrossRefGoogle Scholar
  79. Linnet, K. (2002). Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes. Human Psychopharmacology, 24, 512–517.Google Scholar
  80. Liston, H. L., Markowitz, J. S., & DeVane, L. (2001). Drug glucuronidation in clinical psychopharmacology. Journal of Clinical Psychopharmacology, 21, 500–515.PubMedCrossRefGoogle Scholar
  81. Lorberg, B., Youssef, N. A., & Bhagwagar, Z. (2009). Lamotrigine-associated rash: to rechallenge or not to rechallenge? The International Journal of Neuropsychopharmacology, 12, 257–265.PubMedCrossRefGoogle Scholar
  82. Mackay, F. J., Wilton, L. V., Pearce, G. L., Freemantle, S. N., & Mann, R. D. (1997). Safety of long-term lamotrigine in epilepsy. Epilepsia, 38, 881–886.PubMedCrossRefGoogle Scholar
  83. Malik, S., Arif, H., & Hirsch, L. J. (2006). Lamotrigine and its applications in the treatment of epilepsy and other neurological and psychiatric disorders. Expert Review of Neurotherapeutics, 6, 1609–1627.PubMedCrossRefGoogle Scholar
  84. Maniyar, F., Rooney, C., Lily, O., & Bazaz, R. (2009). Anticonvulsant hypersensitivity syndrome presenting as aseptic meningitis. Journal of Neurology, 256, 1190–1191.PubMedCrossRefGoogle Scholar
  85. Mantegazza, M., Curia, G., Biagini, G., Ragsdale, D. S., & Avoli, M. (2010). Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurology, 9, 413–424.PubMedCrossRefGoogle Scholar
  86. Marcellin, P., de Bony, F., Garret, C., Altman, C., Boige, V., Castelnau, C., et al. (2001). Influence of cirrhosis on lamotrigine pharmacokinetics. British Journal of Clinical Pharmacology, 51, 410–414.PubMedCrossRefGoogle Scholar
  87. Marson, A. G., Al-Kharusi, A. M., Alwaidh, M., Appleton, R., Baker, G. A., Chadwick, D. W., SANAD Study group, et al. (2007a). The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet, 369, 1016–1026.PubMedCrossRefGoogle Scholar
  88. Marson, A. G., Al-Kharusi, A. M., Alwaidh, M., Appleton, R., Baker, G. A., Chadwick, D. W., SANAD Study group, et al. (2007b). The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblended randomised controlled trial. Lancet, 369, 1000–1015.PubMedCrossRefGoogle Scholar
  89. May, T.W., Rambeck, B., Jurgens, U (1999). Influence of oxcarbamazepine and methosuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study. Therapeutic Drug Monitoring, 21, 175–181.Google Scholar
  90. May, T. W., Korn-Merker, E., & Rambeck, B. (2003). Clinical pharmacokinetics of oxcarbazepine. Clinical Pharmacokinetics, 42, 1023–1042.PubMedCrossRefGoogle Scholar
  91. McKee, J. R., Sunder, T. R., FineSmith, R., Vuong, A., Varner, J. A., Hammer, A. E., & Barrett, P. S. (2003). Lamotrigine as adjunctive therapy in patients with refractory epilepsy and mental retardation. Epilepsy & Behavior, 4, 386–394.CrossRefGoogle Scholar
  92. Meador, K. J., Baker, G. A., Browning, N., Clayton-Smith, J., Combs-Cantrell, D. T., Cohen, M., NEAD Study Group, et al. (2009). Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. The New England Journal of Medicine, 16(360), 1597–1605.CrossRefGoogle Scholar
  93. Merrick, J., Merrick, E., Lunsky, Y., & Kandel, I. (2006). A review of suicidality in persons with intellectual disability. The Israel Journal of Psychiatry and Related Sciences, 43, 258–264.PubMedGoogle Scholar
  94. Messenheimer, J. A. (1998). Rash in adult and pediatric patients treated with lamotrigine. The Canadian Journal of Neurological Sciences, 25, 514–518.Google Scholar
  95. Mockenhaupt, M., Messenheimer, J., Tennis, P., & Schlingmann, J. (2005). Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology, 64, 1134–1138.PubMedCrossRefGoogle Scholar
  96. Mockenhaupt, M., Viboud, C., Dunant, A., Naldi, L., Halevy, S., Bouwes Bavinck, J. N., et al. (2008). Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. The Journal of Investigative Dermatology, 128, 35–44.PubMedCrossRefGoogle Scholar
  97. Mula, M., & Sander, J. W. (2007). Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Safety, 30, 555–567.PubMedCrossRefGoogle Scholar
  98. Newport, D. J., Pennell, P. B., Calamaras, M. R., Ritchie, J. C., Newman, M., Knight, B., et al. (2008). Lamotrigine in breast milk and nursing infants: determination of exposure. Pediatrics, 122, e223–e231.PubMedCrossRefGoogle Scholar
  99. Nordmo, E., Aronsen, L., Wasland, K., Småbrekke, L., & Vorren, S. (2009). Severe apnea in an infant exposed to lamotrigine in breast milk. The Annals of Pharmacotherapy, 43, 1893–1897.PubMedCrossRefGoogle Scholar
  100. O’Neill, A., & de Leon, J. (2007). Two case reports of oral ulcers with lamotrigine several weeks after oxcarbazepine withdrawal. Bipolar Disorders, 9, 310–313.PubMedCrossRefGoogle Scholar
  101. Odishaw, J., & Chen, C. (2000). Effects of steady-state bupropion on the pharmacokinetics of lamotrigine in healthy subjects. Pharmacotherapy, 20, 1448–1453.PubMedCrossRefGoogle Scholar
  102. Ohman, I., Beck, O., Vitols, S., & Tomson, T. (2008). Plasma concentrations of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy. Epilepsia, 49, 1075–1080.PubMedCrossRefGoogle Scholar
  103. Otoul, C., De Smedt, H., & Stockis, A. (2007). Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy. Epilepsia, 48, 2111–2115.PubMedCrossRefGoogle Scholar
  104. Ouellet, G., Tremblay, L., & Marleau, D. (2009). Fulminant hepatitis induced by lamotrigine. Southern Medical Journal, 10, 82–84.CrossRefGoogle Scholar
  105. Patsalos, P. N., Berry, D. J., Bourgeois, B. F., Cloyd, J. C., Glauser, T. A., Johannessen, S. I., et al. (2008). Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia, 49, 1239–1276.PubMedCrossRefGoogle Scholar
  106. Pennell, P. B., Peng, L., Newport, D. J., Ritchie, J. C., Koganti, A., Holley, D. K., et al. (2008). Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. Neurology, 70, 2130–2136.PubMedCrossRefGoogle Scholar
  107. Pisani, F., Oteri, G., Russo, M. F., Di Perri, R., Perucca, E., & Richens, A. (1999). The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia, 40, 1141–1146.PubMedCrossRefGoogle Scholar
  108. Punyawudho, B., Ramsay, R. E., Macias, F. M., Rowan, A. J., Collins, J. F., Brundage, R. C., et al. (2008). Population pharmacokinetics of lamotrigine in elderly patients. Journal of Clinical Pharmacology, 48, 455–463.PubMedCrossRefGoogle Scholar
  109. Ramaratnam, S., Marson, A. G., & Baker, G. A. (2001). Lamotrigine add-on for drug-resistant partial epilepsy. The Cochrane Database of Systematic Reviews, 3, CD001909.Google Scholar
  110. Reimers, A., Helde, G., & Brodtkorb, E. (2005). Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. Epilepsia, 46, 1414–1417.PubMedCrossRefGoogle Scholar
  111. Reimers, A., Skogvoll, E., Sund, J. K., & Spigset, O. (2005). Drug interactions between lamotrigine and psychoactive drugs: evidence from a therapeutic drug monitoring service. Journal of Clinical Psychopharmacology, 25, 342–348.PubMedCrossRefGoogle Scholar
  112. Reinsberger, C., Dorn, T., & Krämer, G. (2008). Smoking reduces serum levels of lamotrigine. Seizure, 17, 651–653.PubMedCrossRefGoogle Scholar
  113. Rogwaski, M. A., & Löscher, W. (2004). The neurobiology of antiepileptic drugs. Nature Reviews. Neuroscience, 5, 553–564.CrossRefGoogle Scholar
  114. Rowland, A., Elliot, D. J., Williams, J. A., Mackenzie, P. I., Dickinson, R. G., & Miners, J. O. (2006). In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metabolism and Disposition, 34, 1055–1062.PubMedGoogle Scholar
  115. Sachs, G., Bowden, C., Calabrese, J. R., Ketter, T., Thompson, T., White, R., et al. (2006). Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder. Bipolar Disorders, 8, 175–181.PubMedCrossRefGoogle Scholar
  116. Saneto, R. P., & Anderson, G. D. (2009). Onset of action and seizure control in Lennox-Gaustaut syndrome: focus on rufinamide. Therapeutics and Clinical Risk Management, 5, 271–280.PubMedCrossRefGoogle Scholar
  117. Schieber, F. C., Boulton, D. W., Balch, A. H., Croop, R., Mallikaarjun, S., Benson, J., et al. (2009). A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder. Human Psychopharmacology, 24, 145–152.PubMedCrossRefGoogle Scholar
  118. Seo, H. J., Chiesa, A., Lee, S. J., Patkar, A. A., Han, C., Masand, P. S., et al. (2011). Safety and tolerability of lamotrigine: results from 12 placebo-controlled clinical trials and clinical implications. Clinical Neuropharmacology, 34, 39–47.PubMedCrossRefGoogle Scholar
  119. Sharma, C., Dubey, R., Kumar, H., & Saha, N. (2005). Food reduces the bioavailability of lamotrigine. The Indian Journal of Medical Research, 121, 659–664.PubMedGoogle Scholar
  120. Shor, S., Koren, G., & Nulman, I. (2007). Teratogenicity of lamotrigine. Canadian Family Physician, 53, 1007–1009.PubMedGoogle Scholar
  121. Sidhu, J., Job, S., Bullman, J., Francis, E., Abbott, R., & Ascher, J. G. (2006). Pharmacokinetics and tolerability of lamotrigine and olanzapine coadministered to healthy subjects. British Journal of Clinical Pharmacology, 61, 420–426.PubMedCrossRefGoogle Scholar
  122. Sidhu, J., Job, S., Singh, S., & Philipson, R. (2006). The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. British Journal of Clinical Pharmacology, 61, 191–199.PubMedCrossRefGoogle Scholar
  123. Simister, R. J., Sander, J. W., & Koepp, M. J. (2007). Long-term retention rates of new antiepileptic drugs in adults with chronic epilepsy and learning disability. Epilepsy & Behavior, 2, 336–339.CrossRefGoogle Scholar
  124. Sirven, J. I., Fife, T. D., Wingerchuk, D. M., & Drazkowski, J. F. (2007). Second-generation antiepileptic drugs’ impact on balance: a meta-analysis. Mayo Clinic Proceedings, 82, 40–47.PubMedGoogle Scholar
  125. Spina, E., D’Arrigo, C., Migliardi, G., Santoro, V., Muscatello, M. R., Micò, U., et al. (2006). Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. Therapeutic Drug Monitoring, 28, 599–602.PubMedCrossRefGoogle Scholar
  126. Spina, E. A., & de Leon, J. (2007). Metabolic drug interactions with newer antipsychotics: a comparative review. Basic & Clinical Pharmacology & Toxicology, 100, 4–22.CrossRefGoogle Scholar
  127. Spina, E., Santoro, V., & D’Arrigo, C. (2008). Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clinical Therapeutics, 30, 1206–1227.PubMedCrossRefGoogle Scholar
  128. Stafstrom, C. E. (2009). Update on the management of Lennox-Gastaut syndrome with a focus on rufinamide. Neuropsychiatric Disease and Treatment, 5, 547–551.PubMedCrossRefGoogle Scholar
  129. Steinbaugh, L., & Szaflarski, J. P. (2010). Adjunctive therapy for the treatment of primary generalized tonic-clonic seizures: focus on once-daily lamotrigine. Drug Design, Development and Therapy, 4, 337–342.PubMedGoogle Scholar
  130. Subuh Surja, A. A., Brotzge, K. E., & El-Mallakh, R. S. (2005). Serious rash with lamotrigine after carbamazepine discontinuation: a case report (letter). The Journal of Clinical Psychiatry, 66, 400–401.PubMedCrossRefGoogle Scholar
  131. Sunder, T. R., McKee, J. R., Hammer, A. E., & Vuongc, A. (2006). Efficacy and tolerability of adjunctive lamotrigine for refractory epilepsy in institutional or community residents with mental retardation. Current Medical Research and Opinion, 22, 693–702.PubMedCrossRefGoogle Scholar
  132. Suppes, T., Dennehy, E. B., Swann, A. C., Bowden, C. L., Calabrese, J. R., Hirschfeld, R. M., Texas consensus conference panel on medication treatment of bipolar disorder, et al. (2002). Report of the Texas consensus conference panel on medication treatment of bipolar disorder 2000. The Journal of Clinical Psychiatry, 63, 288–299.PubMedCrossRefGoogle Scholar
  133. Tengstrand, M., Star, K., van Puijenbroek, E. P., & Hill, R. (2010). Alopecia in association with lamotrigine use: an analysis of individual case safety reports in a global database. Drug Safety, 33, 653–658.PubMedCrossRefGoogle Scholar
  134. Theis, J. G., Sidhu, J., Palmer, J., Job, S., Bullman, J., & Ascher, J. (2005). Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine. Neuropsychopharmacology, 30, 2269–2274.PubMedCrossRefGoogle Scholar
  135. Thibert, R. L., Conant, K. D., Braun, E. K., Bruno, P., Said, R. R., Nespeca, M. P., et al. (2009). Epilepsy in angelman syndrome: a questionanaire-based assessment of the natural history and current treatment options. Epilepsia, 50, 2369–2376.PubMedCrossRefGoogle Scholar
  136. Thomas, S. P., Nandhra, H. S., & Jayaraman, A. (2010). Systematic review of lamotrigine augmentation of treatment resistant unipolar depression (TRD). Journal of Mental Health, 19, 168–175.PubMedCrossRefGoogle Scholar
  137. Tiihonen, J., Wahlbeck, K., & Kiviniemi, V. (2009). The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophrenia Research, 109, 10–14.PubMedCrossRefGoogle Scholar
  138. Titlic, M., Jukic, I., Tonkic, A., Josipovic-Jelic, Z., Boschi, V., Mihalj, M., et al. (2008). Lamotrigine in the treatment of pain syndromes and neuropathic pain. Bratislavské Lekárske Listy, 109, 421–424.PubMedGoogle Scholar
  139. Tjia-Leong, E., Leong, K., & Marson, A. G. (2010). Lamotrigine adjunctive therapy for refractory generalized tonic-clonic seizures. The Cochrane Database of Systematic Reviews, 12, CD007783.Google Scholar
  140. Tomson, T. (2009). Which drug for the pregnant woman with epilepsy? The New England Journal of Medicine, 360, 1667–1669.PubMedCrossRefGoogle Scholar
  141. Tomson, T., Luef, G., Sabers, A., Pittschieler, S., & Ohman, I. (2006). Valproate effects on kinetics of lamotrigine in pregnancy and treatment with oral contraceptives. Neurology, 67, 1297–1299.PubMedCrossRefGoogle Scholar
  142. Tomson, T., Lukic, S., & Ohman, I. (2010). Are lamotrigine kinetics altered in menopause? Observations from a drug monitoring database. Epilepsy & Behavior, 19, 86–88.CrossRefGoogle Scholar
  143. US Department of Mental Health and Human Services (2008). Statistical review and evaluation: antiepileptic drugs and suicidality. Accessed 5 Apr 2011.
  144. Vajda, F. J., Graham, J. E., Hitchcock, A. A., O’Brien, T. J., Lander, C. M., & Eadie, M. J. (2010). Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. Seizure, 19, 558–561.PubMedCrossRefGoogle Scholar
  145. van der Lee, M. J., Dawood, L., ter Hofstede, H. J., de Graaff-Teulen, M. J., van Ewijk-Beneken Kolmer, E. W., Caliskan-Yassen, N., et al. (2006). Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. Clinical Pharmacology and Therapeutics, 80, 159–168.PubMedCrossRefGoogle Scholar
  146. van der Loos, M. L., Mulder, P. G., Hartong, E. G., Blom, M. B., Vergouwen, A. C., de Keyzer, H. J., LamLit Study Group, et al. (2009). Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter double-blind placebo-controlled trial. The Journal of Clinical Psychiatry, 70, 223–231.PubMedCrossRefGoogle Scholar
  147. Vigo, D. V., & Baldessarini, R. J. (2009). Anticonvulsants in the treatment of major depressive disorder: an overview. Harvard Review of Psychiatry, 17, 231–241.PubMedCrossRefGoogle Scholar
  148. Warren, Z. E., Sanders, K. B., & Veenstra-VanderWeele, J. (2010). Identity crisis involving body image in a young man with autism. The American Journal of Psychiatry, 167, 1299–1303.PubMedCrossRefGoogle Scholar
  149. Wegner, I., Edelbroek, P. M., Bulk, S., & Lindhout, D. (2009). Lamotrigine kinetics within the menstrual cycle, after menopause, and with oral contraceptives. Neurology, 73, 1388–1393.PubMedCrossRefGoogle Scholar
  150. Weintraub, D., Buchsbaum, R., Resor, S. R., Jr., & Hirsch, L. J. (2005). Effect of antiepileptic drug comedication on lamotrigine clearance. Archives of Neurology, 62, 1432–1436.PubMedCrossRefGoogle Scholar
  151. Weintraub, D., Buchsbaum, R., Resor, S. R., Jr., & Hirsch, L. J. (2007). Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy. Epilepsy & Behavior, 10, 105–110.CrossRefGoogle Scholar
  152. Wiffen, P. J., Derry, S., & Moore, R. A. (2011). Lamotrigine for acute and chronic pain. The Cochrane Database of Systematic Reviews, 2, CD006044.Google Scholar
  153. Wong, I. C. K., Mawer, G. E., & Sander, J. W. (1999). Factors influencing the incidence of lamotrigine-related skin rash. The Annals of Pharmacotherapy, 33, 1037–1042.PubMedCrossRefGoogle Scholar
  154. Working Group of the International Association of the Scientific Study of Intellectual Disability. (2001). Clinical guidelines for the management of epilepsy in adults with an intellectual disability. Seizure, 10, 401–409.CrossRefGoogle Scholar
  155. Zaatreh, M. M. (2003). Anticonvulsant-induced dyskinesia. Expert Opinion on Drug Safety, 2, 385–393.PubMedCrossRefGoogle Scholar
  156. Zaccara, G., Gangemi, P. F., & Cincotta, M. (2008). Central nervous system adverse effects of new antiepileptic drugs. A meta-analysis of placebo-controlled studies. Seizure, 17, 405–421.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Jose de Leon
    • 1
  1. 1.Department of Psychiatry College of MedicineUniversity of KentuckyLexingtonUSA

Personalised recommendations